Institutional
Foresite Capital Management VI LLC
CIK 0002013341
$460.3M
Reported AUM
17
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Foresite Capital Management VI LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management VI LLC closed its position in RAPT Therapeutics, Inc. RAPT, reducing exposure by $52.9M. The fund also exited its holdings in Natera, Inc. NTRA for $15.4M and Atai Beckley N.V. ATAI for $11.2M. Offsetting these sales, the fund established new positions in Minerva Neurosciences, Inc. NERV for $11.9M and Celldex Therapeutics, Inc. CLDX for $10M. Additionally, the fund increased its share count in Corvus Pharmaceuticals, Inc. CRVS by 32.6%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CGON | CG Oncology, Inc. | $53.72 | -4.23% | 99.63% | 20.15% | $150.3M | 32.67% | — | HELD |
| 2 | ALMS | ALUMIS INC. | $19.06 | -6.52% | 430.92% | 54.96% | $93.6M | 20.33% | — | HELD |
| 3 | CNTA | Centessa Pharmaceuticals plc | $39.62 | -0.45% | 232.38% | 91.96% | $54.2M | 11.77% | — | HELD |
| 4 | CRVS | Corvus Pharmaceuticals, Inc. | $11.12 | -5.12% | 184.40% | 432.06% | $26.8M | 5.82% | +450,000 | +32.6% |
| 5 | DNLI | Denali Therapeutics Inc. | $19.52 | -3.08% | 32.79% | -61.75% | $23.2M | 5.05% | +209,971 | +21.0% |
| 6 | AGIO | AGIOS PHARMACEUTICALS, INC. | $28.29 | -1.74% | -17.59% | -41.17% | $17.8M | 3.86% | −5,000 | −0.9% |
| 7 | VSTM | Verastem, Inc. | $3.71 | -3.89% | -42.21% | -90.43% | $16.7M | 3.62% | +11,511 | +0.4% |
| 8 | KYMR | Kymera Therapeutics, Inc. | $74.13 | -0.64% | 55.67% | 23.18% | $12.2M | 2.65% | — | HELD |
| 9 | NERV | Minerva Neurosciences, Inc. | $4.96 | 3.77% | 169.57% | -66.30% | $12.0M | 2.60% | +1,986,600 | NEW |
| 10 | CLDX | Celldex Therapeutics, Inc. | $28.62 | -4.38% | 34.05% | -34.58% | $10.0M | 2.18% | +315,913 | NEW |
| 11 | ATAI | AtaiBeckley Inc. | $3.95 | -12.22% | 63.90% | -74.52% | $9.7M | 2.12% | +2,750,000 | NEW |
| 12 | HNGE | Hinge Health, Inc. | $63.62 | 1.02% | 63.59% | 22.94% | $8.5M | 1.85% | +85,400 | +63.3% |
| 13 | CRNX | Crinetics Pharmaceuticals, Inc. | $32.92 | -4.94% | -0.27% | 83.09% | $7.7M | 1.67% | +212,010 | NEW |
| 14 | OKUR | OnKure Therapeutics, Inc. | $4.19 | -2.56% | 45.49% | -94.88% | $6.0M | 1.30% | +1,445,783 | NEW |
| 15 | JBIO | Jade Biosciences, Inc. | $16.94 | -4.51% | 135.61% | -96.13% | $4.5M | 0.98% | +320,000 | NEW |
| 16 | GHRS | GH Research PLC | $21.43 | -7.83% | 71.44% | 8.78% | $4.4M | 0.96% | +315,492 | NEW |
| 17 | ZURA | Zura Bio Ltd | $3.40 | -7.36% | 169.84% | -50.07% | $2.7M | 0.58% | +450,000 | NEW |
| 18 | RAPT | RAPT Therapeutics, Inc. | — | — | — | — | — | — | −1,562,500 | EXITED |
| 19 | NTRA | Natera, Inc. | $215.31 | -3.06% | 31.48% | 88.01% | — | — | −67,356 | EXITED |
| 20 | ATAI | Atai Beckley N.V. | $3.95 | -12.22% | 63.90% | -74.52% | — | — | −2,750,000 | EXITED |
Source: SEC EDGAR · accession 0001104659-26-062467. 13F discloses long positions only — shorts, foreign equities, and options are excluded.